HER2 negative breast cancer

10 trials 2 recruiting MedDRA PT
10 Registered trials
2 Recruiting
9 Unique sponsors
11 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 5
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
CDK inhibitor 2 substances
SERD 1 substance
Unknown / small molecule 1 substance
Alkylating agent 1 substance
Anthracycline 1 substance
Taxane 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Platinum compound 1 substance
Supportive / diluent 1 substance
mTOR inhibitor 1 substance
Phase III: 1 Phase II: 5 Phase I/II: 1 Phase IV: 1 Phase I (Other): 2

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

1 trial
  • ETOP IBCSG Partners Foundation Academic
    PALBOCICLIB
    2024-510776-20-00 5 countries 2019 n=381
    Ended

Phase II

5 trials
  • Institut Curie Academic
    FULVESTRANT; MILADEMETAN
    2022-502360-21-00 1 country 2023 n=48
    Ended
  • Institut fuer Frauengesundheit GmbH Academic
    IMP not specified
    2024-519350-37-00 1 country n=89
    Ended
  • Institut Paoli Calmettes Academic
    CYCLOPHOSPHAMIDE; EPIRUBICIN HYDROCHLORIDE; PACLITAXEL; PEMBROLIZUMAB
    2024-514899-41-00 1 country 2024 n=72
    Recruiting
  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Academic
    CARBOPLATIN; PACLITAXEL; PEMBROLIZUMAB; SODIUM CHLORIDE
    2023-504145-31-00 1 country 2024 n=78
    Recruiting
  • Orszagos Onkologiai Intezet Academic
    EVEROLIMUS
    2023-505590-33-06 1 country n=64
    Pending

Phase I/II

1 trial
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended

Phase IV

1 trial
  • GE Healthcare Limited Commercial
    IMP not specified
    2024-517400-11-00 1 country 2024 n=165
    Ended

Phase I (Other)

2 trials
  • Pfizer Inc. Commercial
    IMP not specified
    2024-514169-21-00 1 country 2024 n=12
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-518134-92-00 1 country 2025 n=10
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 2 Phase I (Other) 0
GE Healthcare Limited Commercial 1 Phase IV 0
Cyclacel Limited Commercial 1 Phase I/II 0
Institut Curie Academic 1 Phase II 0
Institut fuer Frauengesundheit GmbH Academic 1 Phase II 0
Institut Paoli Calmettes Academic 1 Phase II 1
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Academic 1 Phase II 1
Orszagos Onkologiai Intezet Academic 1 Phase II 0
ETOP IBCSG Partners Foundation Academic 1 Phase III 0
New trials by year
2019
1
2022
1
2023
1
2024
4
2025
1
← All indication landscapes